ACTFusion™

Precision Medicine Aimed At New Genomic Mutations-Fusion Genes

Seizes Opportunities for New Targeted Treatment

In the history of cancer treatment, precision medicine is now endorsed as a modern and preferred way for a healthcare system to take care of its cancer patients. Challenges in identifying the right drug for every cancer patient, as new drugs are emerging for specific genomic mutations, can be tackled strategically by obtaining a cancer patient's unique cancer genomic profile. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well, as these have been commitments of the USFDA from 2018. The wave of precision medicine has also increased the approvals of companion diagnostics, which has resulted in ACT Genomics' genomic profiling service being on the waiting list for US FDA approval.

Why You Need to Know About Precision Medicine

The top global pharma companies are increasingly conducting clinical trials using precision medicine, which requires a cancer patient's genomic information through genomic profiling. This evolution has been felt by most hospitals, so it is increasingly more likely that genomic profiling will be required if you wish to try a new treatment option.

What are Your Chances for Significant Tumor Shrinkage?

The chances of tumor shrinking with targeted therapy increase when something is found at which to aim. In addition to the common genomic alterations, such as a point mutation, insertion and deletion, a fusion gene, which is formed by chromosomal translocation, is newly identified as a target for tumor growth. The fusion gene is known to be complicated, includes hundreds of transcripts and is found in a wide range of cancer types to differing degrees. The highest prevelance of fusion genes are 15% in thyroid cancer and 10% in non-small cell lung cancer. For patients with fusion genes across cancer types, the good news is that the first tumor agnostic treatment has shown significant tumor shrinkage in 17 cancer types for patients with NTRK1/2/3 fusion, and it also works on ALK and ROS1 fusions. This tumor agnostic treatment was approved by the US FDA in 2018. For patients with RET, MET, NRG1 fusion, more global clinical trials await registration. 

Common Problems in Cancer Treatment

∙ Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results.
∙ Complications and metastases make it difficult to determine an appropriate drug.
∙ Ineffective treatment and cancer relapse after targeted therapy.

Diagnostic Solutions for Various Cancers

Through next-generation sequencing (NGS), ACTFusion™ fusion gene testing decodes 13 fusion genes and more than 350 transcripts to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.

ACTFusion™ is suitable for breast, lung, colon cancers and other solid tumors. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.

Treatment Advantages from Targeted Genomic Profiling

✔ More humane process: Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of various fusion genes.

✔ More ideal treatment: Nominates proper targeted options.

✔ More intelligent budgeting: Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.

Type of patients
∙ All major solid tumors 
∙ Newly diagnosed, advanced, recurrent and metastatic cancer 

Specimen requirements
Tumor tissue(FFPE)

Turnaround time
10 working days*